A recent study reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle programs.
Research printed in a major medical journal demonstrates that while overweight people can lose about a fifth of their total mass while on the medication, the weight comes back at an estimated rate of nearly a kilo each month once they quit.
"Users buying such medications need to be aware of the potential of fast weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
This pace of regain suggests a reversion to original mass within about 18 months.
Comparing Therapies
The study, which examined dozens of trials involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.
The team emphasize that individuals who lose weight through dieting generally experience a more gradual weight regain—around 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Experts propose the mode of action of the injections accounts for the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 concentrations far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication means appetite is uncontrolled, making overeating much more probable."
An Ongoing Condition?
The NHS advise the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy is often life-long.
This opinion is supported by drug manufacturers, who say that the results "highlight the persistent character of excess weight," comparing it to managing diseases like high blood pressure.
User Testimonies
People who have stopped the jabs report a intense return of appetite.
"It was like something activating and you become starving," described one woman.
The struggle is worsened if users have not adopted lasting dietary or behavioural changes during therapy.
Significant Interest
Survey data indicate that millions of people in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is more common among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a permanent cure and long-term success likely depends on combined behavioural support.
